Research and Development Agreements - Schedule of Deferred Revenue and Accounts Receivable Balances from the Research and Development Agreements (Detail) - USD ($) $ in Thousands |
Sep. 30, 2019 |
Dec. 31, 2018 |
|---|---|---|
| Liabilities | ||
| Deferred revenue, current | $ 11,956 | $ 26,231 |
| Deferred revenue, non-current | 1,236 | 2,670 |
| Takeda Pharmaceuticals Inc | ||
| Assets | ||
| Unbilled revenue | 0 | 240 |
| Liabilities | ||
| Deferred revenue, current | 11,735 | 26,231 |
| Deferred revenue, non-current | 1,236 | 2,670 |
| Total deferred revenue | $ 12,971 | $ 28,901 |
| X | ||||||||||
- Definition Unbilled revenue related to collaborative agreements. No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|